INTRODUCTION
Severe pulmonary hemorrhage (PH) is a life-threatening event that sometimes occurs in very low birth weight (VLBW) infants and carries mortality as high as 50%. 1 It is characterized by acute deterioration in pulmonary function, bleeding from the lungs as evidenced by suctioning or aspiration of fresh blood, cardiovascular instability and appearance of new pulmonary shadows on chest radiograph. 2 The frequency of PH in VLBW infants treated for respiratory distress syndrome (RDS) varies from 2% to 12%. 1, 3 The precise etiology of PH is unclear and there is presently no consensus on the treatment. Conventional therapy includes assisted ventilation, increased positive end expiratory pressure (PEEP) and transfusion of blood and blood products. Activated recombinant factor VII (rFVIIa) is a low-volume alternate to blood products and is an effective pan-hemostatic agent. It is approved for use in severe, life-threatening hemorrhages in individuals with hemophilia A and B with and without inhibitors. 4 It has also been found useful in nonhemophiliacs with life-threatening hemorrhage. 5 In this communication, we describe two VLBW infants with severe PH that did not respond to conventional therapy but were successfully treated with rFVIIa.
CASE REPORTS
Case 1 was a VLBW, male infant born at 27 weeks' gestation. The pregnancy was complicated by severe pre-eclampsia and mother received a course of antenatal steroids in the week before delivery. Delivery was by emergency cesarean section due to severe preeclampsia and breech presentation. Apgar scores were 8 and 9 at 1 and 5 minutes, respectively. Umbilical arterial blood gases were normal: pH -7.33, PCO 2 -50, PO 2 -17, base excess -À1. Birth weight was 679 g; he was small-for-gestational age. Early in his hospital course, he received two doses of surfactant for RDS and required moderate ventilatory support. He was on vasopressors for hypotension and was treated with a course of indomethacin for closure of a clinically significant patent ductus arteriosus on the second and third days of life. He had normal hemoglobin (Hgb) and hematocrit (Hct) (13.9 g/dl and 43.3%, respectively) at birth; however, he was neutropenic with an absolute neutrophil count (ANC) of 650/mm 3 , thrombocytopenic (platelet count 82 to 164Â10 3 /mm 3 ), and received a 7-day course of antibiotics for suspected sepsis. He developed severe lung disease complicated by pulmonary interstitial emphysema (PIE) in the second week of life. His head ultrasound scans were negative for intraventricular hemorrhage (IVH). He had received multiple transfusions of packed red cells (PRCs), platelets and fresh frozen plasma (FFP).
On day of 14 of life, following an oxygen desaturation, approximately 5 ml fresh blood was suctioned from his endotracheal tube (ETT) and he became hypotensive. A coagulation profile revealed mild thrombocytopenia of 131,000/mm 3 and a normal prothrombin time (PT; 14.0 seconds), activated partial thromboplastin time (PTT; 44.1 seconds) and fibrinogen (267 mg/dl). D -Dimers were positive. His Hgb and Hct were 13.1 g/dl and 40.1%, respectively. He required increased ventilatory support with increased positive end expiratory pressure, and was transfused packed red cells (for mild anemia), platelets and fresh frozen plasma. Copious amounts of fresh blood continued to appear in the endotracheal tube and his cardiovascular status remained unstable in spite of above measures. Informed consent for the compassionate use of rFVIIa was then obtained from parents. Thirty-five micrograms (50 g/kg per dose)
Clinically apparent pulmonary hemorrhage ( PH ) occurs in 5% to 7% of very low birth weight ( VLBW ) infants with respiratory distress syndrome ( RDS ). It is associated with a mortality rate as high as 50% and significant pulmonary and central nervous system morbidities. There is no consensus on treatment modality. We present two VLBW infants with severe PH that did not respond to conventional treatment but were successfully treated with activated recombinant factor VII ( rFVIIa ). No untoward side effects were noted. Journal of Perinatology ( 2002 ) 
twice daily, 3 hours apart, was administered intravenously for three consecutive days. Plasma FVII level was 53% before administration of rFVIIa and PT was checked before each dosage administration. The patient's PT shortened from 14 to 8.7 seconds after the first dose; the bleeding stopped as evidenced by the rapid disappearance of fresh blood from tracheal aspirates on suctioning. Table 1 shows the Hgb, Hct and coagulation parameters pre-and post-rFVIIa administration. The Hct and Hgb stabilized and the thrombocytopenia resolved. He had laser surgery for retinopathy of prematurity (ROP), developed bronchopulmonary dysplasia and was discharged home on supplemental oxygen after 161 days of hospital stay. Case 2 was a VLBW female infant born at 24 weeks' gestation by emergency cesarean section secondary to breech presentation and preterm labor. Her Apgar scores were 6, 5 and 7 at 1, 5 and 10 minutes, respectively. Umbilical arterial blood gases were normal: pH -7.37, PCO 2 -41, PO 2 -24, base excess -À1. Birth weight (625 g) was appropriate for gestational age. She received a dose of surfactant for RDS, following which she required minimal ventilatory support. She received dopamine infusion briefly for hypotension and two doses of indomethacin for closure of patent ductus arteriosus. Antibiotic and antifungal (Fluconazole) agents were started for presumed sepsis; however, the antibiotics were discontinued after 72 hours, as bacterial cultures were negative. At the age of 15 days, the baby experienced multiple oxygen desaturation episodes and an increased need for ventilatory support. Approximately 4 ml of fresh blood was suctioned from the endotracheal tube. A CBC revealed a total white cell count of 22.2Â10 3 /mm 3 ; Hgb 10.2 g/dl, Hct 30.8% and platelet count 173Â10 3 /mm 3 . Liver enzymes were normal and coagulation profile was normal -PT -12.3 seconds, PTT -45.7 seconds and fibrinogen -360 mg/dl. Packed red cells were transfused to correct anemia, but despite volume replacement, she developed hypotension and required inotropic support. A repeat echocardiogram confirmed that the ductus arteriosus had reopened and she was treated with a second course of indomethacin. The PH persisted after ductal closure documented by echocardiogram. A chest X-ray on day 18 of life showed complete opacification of the lung fields, her cardiovascular status remained unstable and Hct and platelet count had dropped to 36% and 96,000/mm 3 , respectively. She received packed red cells and platelet transfusions for the anemia and thrombocytopenia. As the infant continued to have bloody tracheal aspirates, informed consent was obtained from the family for the use of rFVIIa on compassionate grounds. Treatment with rFVIIa was initiated at a dose of 50 g/kg per dose every 3 hours for a period of 48 hours. Pretreatment plasma FVII level was 71%. Blood counts and PT were monitored during therapy. Table 1 shows the Hgb, Hct and coagulation parameters pre-and post-rFVIIa administration. Blood in the endotracheal tube decreased progressively over the next 72 hours; by day 22 of life, no blood was noted in the endotracheal (EL) aspirates. Patient had laser surgery for severe retinopathy of prematurity, developed chronic lung disease and was discharged home on supplemental oxygen after 148 days in hospital. DISCUSSION PH is a rare but well-recognized complication of prematurity and RDS. The precise etiology remains unclear but antecedents include prematurity, RDS, treatment with surfactant, patent ductus arteriosus, intrauterine growth retardation, birth asphyxia, meconium aspiration, pneumothorax and pulmonary interstitial emphysema. 6 -9 Associated mortality could be as high as 50% in severe cases and up to 60% of survivors develop bronchopulmonary dysplasia. 1 Current management of PH in VLBW infants includes ventilatory support using high positive end expiratory pressure, transfusion of blood and blood products to support the circulation and correct any hemostatic or coagulation defects and evaluation and treatment for patent ductus arteriousus (PDA). 9, 10 These strategies are often ineffective in preventing a poor outcome.
rFVIIa is a vitamin K-dependent glycoprotein structurally similar to plasma-derived human factor VIIa. It is produced in baby hamster kidney (BHK) cells by recombinant DNA technology and the final product is devoid of human proteins and free of exogenous viruses. rFVIIa promotes hemostasis by activating the extrinsic pathway of the coagulation cascade via binding with tissue factor (TF) and forming a hemostatic seal at the site of vascular injury. 11 rFVIIa also binds with low affinity to the surface of activated platelets and, independently of tissue factor, induce the thrombin burst needed for hemostasis. 12 Platelet-localized thrombin generation may therefore also contribute to the action of rFVIIa. The infants presented received platelet transfusions during rFVIIa therapy. It is possible that provision of platelet support during treatment with rFVIIa enhances the effectiveness through interactions with both platelets and tissue factor. 13 rFVIIa is effective in controlling life-threatening hemorrhage in patients with hemophilia A and B with inhibitors, 14 and in nonhemophiliacs with a variety of inherited or acquired hemostatic defects including platelet disorders, liver disease and von Willebrand's disease. 15 -17 Although experience with rFVIIa in the neonatal population is limited, it was used successfully in the treatment of severe intracranial hemorrhage in a VLBW infant with FVII deficiency. 18 Duncan et al. administered rFVIIa, as a single dose of 80 g/kg, to four extremely low birth weight (ELBW) neonates with various types of hemorrhagic complications (two pulmonary, one central nervous system and one non-specified). 19 One newborn with PH did not respond and died despite a second dose of rFVIIa. The second neonate with PH survived. The optimal dose of rFVIIa in low birth weight infants has not been determined. Rare, but potentially severe, side effects including cerebral venous thrombosis have been noted in some adult patients treated with high doses of rFVIIa. However, there are indications from pharmacokinetic studies that young children may require higher doses of rFVIIa due to higher clearance rates and shorter half-life in this population. 20 It was on the basis of these considerations that we administered multiple 50-g/kg doses of rFVIIa. It is possible that a single dose may not produce a sufficiently firm clot and that two or more, albeit lower, doses may be needed to achieve effective hemostasis.
The babies in this report weighed about 0.7 kg when they had PH and therefore required 35 g rFVIIa. As the concentration of the reconstituted vial is 600 g/ml, 0.1 ml of the reconstituted medication was diluted to 1 ml with sterile water and 0.6 ml (36 g) of the diluted medication was administered per dose. The total volume of drug administered was minimal; case 1 received 3.6 ml over 3 days and case 2 got 4.8 ml over a 48-hour period. This is compared to 7 to 10.5 ml of blood and FFP per dose (10 to 15 ml per kilogram). We observed no coagulation or thrombotic complications. Repeated cranial sonograms were negative for intraventricular hemorrhage and white matter injury. In conclusion, rFVIIa appears to be a safe and effective low-volume hemostatic agent in the treatment of severe PH in VLBW infants who fail to respond to ventilator management and use of blood and blood products.
